TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10624546

Group type: EXPERIMENTAL
Intervention: Sertraline (12 weeks treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (12 weeks treatment)
Number of subjects: 0
Study: 8963396

Group type: EXPERIMENTAL
Intervention: Lithotripsy plus ursodeoxycholic acid (UDCA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Lithotripsy alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study: 1971647

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 45

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 45
Study: 7003573

Group type: EXPERIMENTAL
Intervention: Sustained release papaverine preparation
Number of subjects: 14
Study: 30156056

Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg, once daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Metformin (1,000 mg, twice daily)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 84
Study: 27566295

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (AAD)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment
Number of subjects: 294
Study: 25885258

Group type: COMPARATOR
Intervention: Wrist acceleration measurement
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vertical axis chest frequency measurement
Number of subjects: 61

Group type: COMPARATOR
Intervention: Wrist sensor data analysis for gestures
Number of subjects: 61

Group type: COMPARATOR
Intervention: Wrist sensor data analysis for walking
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Wrist acceleration measurement pre- and post-treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Amplitude measurement
Number of subjects: 61

Group type: COMPARATOR
Intervention: Frequency measurement
Number of subjects: 61
Study: 24052565

Group type: EXPERIMENTAL
Intervention: 2g pralidoxime over 20 min, followed by an infusion of 0.5 g/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1g pralidoxime chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20406523

Group type: EXPERIMENTAL
Intervention: Immediate iCBT with e-mail support over 3 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waiting list/delayed treatment control (WL/DTC)
Number of subjects: 76
Study: 19734776

Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.05, 0.1, or 0.2 mg/kg/d
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.2 mg/kg/d
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.1 mg/kg/d
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Long-term rhGH at 0.1 and 0.2 mg/kg/d
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 16711546

Group type: EXPERIMENTAL
Intervention: Metilprednisolone aceponate 0.1%
Number of subjects: 34

Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05%
Number of subjects: 34
Study: 11184219

Group type: EXPERIMENTAL
Intervention: Natural helpers intervention with health and skill-building education over 18 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Natural helpers intervention
Number of subjects: 104
Study: 8880048

Group type: EXPERIMENTAL
Intervention: tramadol controlled release 150 mg (TCR150)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: tramadol controlled release 100 mg (TCR100)
Number of subjects: 20

Group type: COMPARATOR
Intervention: tramadol standard formulation (T100)
Number of subjects: 20
Study: 2051734

Group type: EXPERIMENTAL
Intervention: Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin (1st month 10 mg; 2nd month 20 mg; 3rd month 40 mg day‐1)
Number of subjects: 40
Study: 6825993

Group type: EXPERIMENTAL
Intervention: High-fat diet (60% calories as fat, 20% as carbohydrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-carbohydrate diet (20% calories as fat, 60% as carbohydrate)
Number of subjects: 8
Study: 31495201

Group type: EXPERIMENTAL
Intervention: BL-8040 + G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + G-CSF
Number of subjects: 0
Study: 29215511

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 70
Study: 26598449

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard semi-structured assessment interview
Number of subjects: 42
Study: 25230734

Group type: EXPERIMENTAL
Intervention: sFlt‐1/PlGF ratio
Number of subjects: 1000
Study: 22349746

Group type: EXPERIMENTAL
Intervention: IV paracetamol 15 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV saline infusion 1.5 mL/kg
Number of subjects: 60
Study: 20124113

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Playing table football (control group) for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined exercise and nonexercise schizophrenia group
Number of subjects: 0
Study: 17338766

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > or =30 kg/m(2))
Number of subjects: 476

Group type: COMPARATOR
Intervention: Nonobese patients (BMI <30 kg/m(2))
Number of subjects: 476
Study: 15960429

Group type: EXPERIMENTAL
Intervention: 0.4 g alcohol/kg body weight (females: 10% less)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.7 g alcohol/kg body weight (females: 10% less)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12014907

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 0
Study: 10533993

Group type: EXPERIMENTAL
Intervention: Developmental handling
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional handling
Number of subjects: 38
Study: 7576897

Group type: EXPERIMENTAL
Intervention: Postural Support Nappy (PSN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Nappy (Control)
Number of subjects: 60
Study: 31791113

Group type: EXPERIMENTAL
Intervention: Support for Physician-Assisted Suicide (PAS)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Belief that respect for autonomy justifies PAS
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Intent to prescribe or support PAS if legal
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Mandatory palliative care consultation and independent assessments from two physicians
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Concerns regarding vulnerable populations
Number of subjects: 369
Study: 31535102

Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation without bone grafting (test group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Osteotome sinus floor elevation with bone grafting (control group)
Number of subjects: 12
Study: 28972192

Group type: EXPERIMENTAL
Intervention: Tadalafil 0.3 mg·kg‐1·d‐1
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Tadalafil 0.6 mg·kg‐1·d‐1
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Tadalafil (low-dose)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Tadalafil (high-dose)
Number of subjects: 331
Study: 26939334

Group type: EXPERIMENTAL
Intervention: Acupoint injection at Zusanli (ST 36) combined with electroacupuncture (EA) at Hegu (LI 4) and Sanyinjiao (SP 6)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine respiratory instruction
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acupoint injection and EA
Number of subjects: 84
Study: 22068465

Group type: EXPERIMENTAL
Intervention: Natural interferon α (3 million to 6 million units) administered intramuscularly 3 times a week for 1 year
Number of subjects: 100

Group type: COMPARATOR
Intervention: Follow-up observation until recurrence or metastasis occurred
Number of subjects: 100
Study: 21288972

Group type: EXPERIMENTAL
Intervention: Crystalloid preload
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colloid preload
Number of subjects: 60
Study: 19494743

Group type: EXPERIMENTAL
Intervention: Platelet glue (fibrin glue composite)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (instrumented posterolateral lumbar fusion with artificial bone expander and laminectomy autograft)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Platelet glue
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Platelet glue and Control group
Number of subjects: 67
Study: 17583373

Group type: EXPERIMENTAL
Intervention: Prednisolone alone (P)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisolone plus azathioprine (P/A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisolone plus mycophenolate mofetil (P/MM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisolone plus intravenous cyclophosphamide pulse therapy (P/PC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cytotoxic groups (P/A, P/MM, P/PC)
Number of subjects: 120
Study: 15024666

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC) - 200 mg of ascorbic acid twice a day for 14 days prior to exercise and for 3 days after exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (P) - identical capsules containing 200 mg lactose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study: 11216954

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 9688064

Group type: EXPERIMENTAL
Intervention: New 50 mg tablet formulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Old 50 mg tablet formulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Suspension containing 50 mg/ml of primidone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: New 250 mg tablet formulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Old 250 mg tablet formulation (two lots)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 250 mg tablet from a second manufacturer
Number of subjects: 42
Study: 8081096

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MR) before surgery
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Postoperative neuropsychological assessment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MR) one week after surgery
Number of subjects: 15
Study: 2510223

Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg/kg i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (2 ml 0.9% NaCl)
Number of subjects: 10
Study: 355026

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 375 mg/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 750 mg/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 1,500 mg/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 3,000 mg/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 1,500 mg/day or 17‐24 mg/kg body weight
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 31944270

Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of methotrexate, once weekly for 6 sittings.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment, twice daily for 6 weeks.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of methotrexate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 62
Study: 31240472

Group type: EXPERIMENTAL
Intervention: Plitidepsin 5 mg/m2 on D1 and D15 plus Dexamethasone 40 mg on D1, D8, D15, and D22 (arm A)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Dexamethasone 40 mg on D1, D8, D15, and D22 (arm B)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Plitidepsin plus Dexamethasone (arm A)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Dexamethasone alone (arm B)
Number of subjects: 255
Study: 27495814

Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 40
Study: 26228390

Group type: EXPERIMENTAL
Intervention: Telehealth program (MASTERY©) using a mobile application (Breathe-easy©) and a Bluetooth-enabled device (COPD-6®) for self-monitoring of lung function (FEV1, FEV6) twice daily, recording asthma symptoms and medication usage weekly, and a written asthma action plan (WAAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth program (MASTERY©)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23440337

Group type: EXPERIMENTAL
Intervention: Prime Time intervention (case management and youth leadership programs)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study: 22176722

Group type: EXPERIMENTAL
Intervention: Physical activity intervention based on a pedometer (12-week tailored program encouraging increased walking)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physical activity intervention based on a pedometer
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine postpartum care (control group)
Number of subjects: 66
Study: 17693902

Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET 175 microg/275 mug
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral E2/NET acetate 1 mg/0.5 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 17297830

Group type: COMPARATOR
Intervention: Propofol (0.45 mg x kg(‐1))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine plus Propofol (0.45 mg x kg(‐1) of propofol plus 0.25 mg x kg(‐1) of ketamine)
Number of subjects: 50
Study: 12941060

Group type: EXPERIMENTAL
Intervention: Normal Sleep Onset (NSO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed Sleep Onset (DSO)
Number of subjects: 30
Study: 10625080

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.20‐0.25 mg/kg, 12 hourly)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ibuprofen (5‐10 mg/kg, 24 hourly)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Indomethacin (after 24-h dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Indomethacin (after 48-h dose of saline)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ibuprofen (after 24-h and 48-h doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 33
Study: 9199606

Group type: EXPERIMENTAL
Intervention: Patients with OSA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controls (not known to have OSA)
Number of subjects: 12
Study: 1591054

Group type: EXPERIMENTAL
Intervention: Formestane 62.5 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Formestane 125 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Formestane 250 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Formestane 500 mg
Number of subjects: 43
Study: 2580177

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 15 mg three times a day
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Both hydrochlorothiazide and captopril
Number of subjects: 255
Study: 30382485

Group type: EXPERIMENTAL
Intervention: Midostaurin + cytarabine + daunorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + cytarabine + daunorubicin
Number of subjects: 0
Study: 29879277

Group type: EXPERIMENTAL
Intervention: Oral Valproic Acid (VPA) 500 mg to 1000 mg daily for 12 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26927908

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 345
Study: 25015756

Group type: EXPERIMENTAL
Intervention: Thrombin-based topical hemostatic matrix
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 22645174

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (COLD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CWT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 14
Study: 20452799

Group type: EXPERIMENTAL
Intervention: Guardian RT (real-time glucose-sensor system)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 10
Study: 18582257

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (n = 92)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (n = 88)
Number of subjects: 180
Study: 15200538

Group type: EXPERIMENTAL
Intervention: Capsicum plaster (PAS) applied at the Korean hand acupuncture point (K-A20)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham control (placebo tape at non-acupoints)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo control (placebo tape at non-acupoints)
Number of subjects: 150
Study: 12390621

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 95
Study: 9422557

Group type: EXPERIMENTAL
Intervention: RPA Class I
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: RPA Class III
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: RPA Class IV
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: RPA Class V
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: RPA Class II
Number of subjects: 712

Group type: COMPARATOR
Intervention: Cox model
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: RPA classes
Number of subjects: 712
Study: 7861597

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.25 mg given initially, followed by another 0.25 mg 2 hours later)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous infusion of flumazenil (0.25 mg in 250 ml of lactated Ringer's solution for 2 hours)
Number of subjects: 54
Study: 2618844

Group type: EXPERIMENTAL
Intervention: Heroin cues
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self-ratings after exposure to drug stimuli
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Craving without withdrawal sickness
Number of subjects: 35
Study: 983629

Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Combined ampicillin and cloxacillin
Number of subjects: 107
Study: 30967236

Group type: EXPERIMENTAL
Intervention: Radiation fractionation schedules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gleason grade group
Number of subjects: 0
Study: 29243165

Group type: EXPERIMENTAL
Intervention: Intervention (INT): Counseling/group discussions coupled with supervised exercise tapered to unsupervised exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 27
Study: 26342932

Group type: EXPERIMENTAL
Intervention: Endoscopically procured ATOS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transcranially procured ATOS
Number of subjects: 50
Study: 24628972

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 472
Study: 22150299

Group type: EXPERIMENTAL
Intervention: Left Ventricular Automatic Threshold (LVAT) algorithm
Number of subjects: 70
Study: 21313894

Group type: EXPERIMENTAL
Intervention: M 1.0 (lidocaine 5% and midazolam 1 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: M 0.5 (lidocaine 5% and midazolam 0.5 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (lidocaine 5% plus normal saline)
Number of subjects: 45
Study: 17635430

Group type: EXPERIMENTAL
Intervention: Dexamethasone with dolasetron
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Dexamethasone with haloperidol
Number of subjects: 242

Group type: COMPARATOR
Intervention: Dolasetron alone
Number of subjects: 242

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 242
Study: 16298809

Group type: EXPERIMENTAL
Intervention: Hand Injury Severity Score (HISS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DASH-score (Disabilities of the Arm, Shoulder and Hand)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-36 (Short Form Health Survey)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Costs of care during an emergency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor injuries
Number of subjects: 0
Study: 11852291

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10355240

Group type: EXPERIMENTAL
Intervention: Full attention during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided attention during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect test instructions
Number of subjects: 0
Study: 7577198

Group type: EXPERIMENTAL
Intervention: Whole abdominal radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy with doxorubicin and cisplatin
Number of subjects: 0
Study: 2012823

Group type: EXPERIMENTAL
Intervention: Biofeedback training for facial relaxation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Biofeedback training for facial tension stability
Number of subjects: 29
Study: 6459839

Group type: EXPERIMENTAL
Intervention: L-tryptophan (5 g po as a single dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-tryptophan combined with nicotinamide (a tryptophan pyrrolase inhibitor) administered for 1-3 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31679857

Group type: EXPERIMENTAL
Intervention: Access to green space
Number of subjects: 2354

Group type: COMPARATOR
Intervention: Surrounding greenness (measured by NDVI)
Number of subjects: 2354
Study: 30640156

Group type: EXPERIMENTAL
Intervention: Dual-task balance training (12 weeks, 3 times/week)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Dual-task gait
Number of subjects: 95